This statistic shows the death rate from liver cirrhosis in the U.S. in 2019, by age. According to the data, during that time the highest death rate was 37.9 per 100,000 and was among those aged 75-84 years.

In 2023, the death rate due to alcohol-related liver cirrhosis among those aged 45-54 years was 11.9 per 100,000. This statistic shows the rate of alcohol-related liver cirrhosis deaths in the U.S. in 2023, by age.

Legacy unique identifier: P00204

This statistic displays the number of alcoholic liver disease related deaths in England in 2021, by gender and age. The number of deaths from alcoholic liver disease was significantly higher among men than women. In 2021, 678 men and 401 women aged between 55 and 59 years old died from alcoholic liver disease.

BackgroundLiver cirrhosis mortality number has increased over the last decades. We aimed to estimate the liver cirrhosis mortality rate and its trends for the first time by sex, age, geographical distribution, and cause in Iran.MethodIranian Death Registration System, along with demographic (Complete and Summary Birth History, Maternal Age Cohort and Period methods) and statistical methods (Spatio-temporal and Gaussian process regression models) were used to address the incompleteness and misclassification and uncertainty of death registration system to estimate annual cirrhosis mortality rate. Percentages of deaths were proportionally redistributed into cirrhosis due to hepatitis B, C and alcohol use based on the data from the Global Burden of Disease (GBD) 2010 study.ResultsLiver cirrhosis mortality in elder patients was 12 times higher than that in younger patients at national level in 2015. Over the 26 years, liver cirrhosis mortality in males has increased more than that in females. Plus, the percentage of change in age adjusted mortality rate at provincial levels varied between decreases of 64.53% to nearly 17% increase. Mortality rate has increased until 2002 and then decreased until 2015.The province with highest mortality rate in 2015 has nearly two times greater rate compare to the lowest. More than 60% of liver cirrhosis mortality cases at national level are caused by hepatitis B and C infection. The rate of hepatitis B mortality is four times more than that from hepatitis C.ConclusionThis study demonstrated an increasing and then decreasing pattern in cirrhosis mortality that could be due to national vaccination of hepatitis B program. However monitoring, early detection and treatment of risk factors of cirrhosis, mainly in high risk age groups and regions are essential. Cirrhosis mortality could be diminished by using new non-invasive methods of cirrhosis screening, hepatitis B vaccination, definite treatment of hepatitis C.

This data shows premature deaths (Age under 75) from Liver Disease, numbers and rates by gender, as 3-year moving-averages.

Most liver disease is preventable and much is influenced by alcohol consumption and obesity prevalence, which are both amenable to public health interventions.

Directly Age-Standardised Rates (DASR) are shown in the data (where numbers are sufficient) so that death rates can be directly compared between areas. The DASR calculation applies Age-specific rates to a Standard (European) population to cancel out possible effects on crude rates due to different age structures among populations, thus enabling direct comparisons of rates.

A limitation on using mortalities as a proxy for prevalence of health conditions is that mortalities may give an incomplete view of health conditions in an area, as ill-health might not lead to premature death.

Data source: Public Health England, Public Health Outcomes Framework (PHOF) indicator 4.06i. The data is updated annually.

This statistic shows the number of liver cirrhosis deaths in the U.S. in 2019, by age. According to the data, among those aged 55 to 64 years, ****** deaths occurred due to liver cirrhosis in 2019.

In 2019, the global death rate from liver cirrhosis and other chronic liver diseases was over twice as high in men compared to women. Men reported over 24 deaths per 100,000 population, while women reported 11.7 deaths per 100,000 population. This statistic displays the age-standardized death rate (ASR) of liver cirrhosis and other chronic liver diseases worldwide in 2019, by gender.

BackgroundLiver cirrhosis-related death is a serious threat worldwide. The number of studies exploring the mortality trend of cirrhosis caused by specific etiologies was limited. This study aimed to demonstrate the pattern and trend based on the data of global burden of disease (GBD).MethodsThe data of cirrhosis mortality were collected from the GBD 2017. The Age standardized mortality rate (ASR) and estimated annual percentage changes (EAPC) were used to estimate the temporal trend of liver cirrhosis mortality by etiologies, regions, sociodemographic index (SDI), and sexes.ResultsGlobally, mortality cases of cirrhosis increased by 47.15%. Although the global ASR of cirrhosis mortality remained stable during this period, the temporal trend varied in etiologies. The ASR of mortality caused by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis (NASH) increased with an EAPC of 0.17 (95% CI, 0.14–0.20), 0.20 (95% CI, 0.16–0.24), 1.00 (95% CI, 0.97–1.04), respectively. A decreasing trend of ASR was found among the causes of hepatitis B virus (BV) and other causes. The increased pattern was heterogeneous worldwide. The most pronounced increase trend was found in middle-high SDI regions and Eastern Europe. Contrarily, the most pronounced decrease trend was found in low SDI regions and Western Sub-Saharan Africa.ConclusionCirrhosis is still a public health problem. The growth trend of cirrhosis mortality caused by HCV was slowed by promoting direct-acting antiviral therapy. Unfortunately, we observed an unfavorable trend in etiologies for alcohol consumption and NASH, which indicated that more targeted and specific strategies should be established to limit alcohol consumption and promote healthy lifestyles in high-risk countries, especially in middle-high SDI regions and Eastern Europe.

In 2023, the age-specific mortality rate of chronic liver disease and cirrhosis at all ages in Canada decreased by *** deaths (***** percent) compared to 2022. Nevertheless, the last two years recorded a significantly higher age-specific mortality rate than the preceding years.

Liver cirrhosis is a significant yet largely preventable and underappreciated cause of global health loss. This study aimed to profile the global and regional burdens of liver cirrhosis between 2010 and 2019 and the contributions of various aetiologies. Data on the incidence, mortality, and disability-adjusted life years (DALYs) of cirrhosis were obtained from the Global Burden of Disease 2019 study. The burden of cirrhosis was estimated by age, sex, region, aetiology, and socio-demographic index (SDI). The temporal trend was quantified using the annual percentage changes (APC.) Globally, there were 2.05 million new cases and 1.47 million deaths due to cirrhosis in 2019. From 2010 to 2019, the age-standardized incidence rate (ASIR) for cirrhosis increased slightly from 25.19 to 25.35 worldwide, while the age-standardized death rate (ASDR) and age-standardized DALYs (ASDALYs) decreased from 20.37 to 18.00 and 639.86 to 560.43, respectively. Cirrhosis incidence, mortality and DALYs were consistently higher in males than females. Stratification according to the socio-demographic index (SDI) revealed that low SDI countries had the highest ASDR and ASDALYs in 2019, while middle SDI countries had the highest ASIR. Regarding the aetiology of cirrhosis, hepatitis C accounted for the largest proportion of cirrhosis-related incidence (26.9%), death (26.8%) and DALYs (26.3%); however, non-alcoholic fatty liver disease (NAFLD) exhibited a rapidly growing cause of incident cirrhosis (+26.7%), cirrhosis-related death (+25.1%), and DALYs (+21.0%) worldwide during this period. The ASIR for NAFLD also significantly increased with APC 1.080 over the study period. Albeit the global burden of cirrhosis incidence increased from 2010 to 2019, cirrhosis-associated deaths and DALYs declined significantly. Notably, NAFLD exhibited the most significant increase as a contributor to cirrhosis worldwide. Global burden of cirrhosis incidence increased from 2010 to 2019.Cirrhosis-associated death and DALYs declined significantly during this period.Non-alcoholic fatty liver disease (NAFLD) exhibited the most significant increase as a contributor to cirrhosis worldwide. Global burden of cirrhosis incidence increased from 2010 to 2019. Cirrhosis-associated death and DALYs declined significantly during this period. Non-alcoholic fatty liver disease (NAFLD) exhibited the most significant increase as a contributor to cirrhosis worldwide.

National and provincial age standardized mortality rate in Iran (per 100,000) for both sexes and the percentage of change (Δ).

Death rate of a population adjusted to a standard age distribution. As most causes of death vary significantly with people's age and sex, the use of standardised death rates improves comparability over time and between countries, as they aim at measuring death rates independently of different age structures of populations. The standardised death rates used here are calculated on the basis of a standard European population (defined by the World Health Organization). Detailed data for 65 causes of death are available in the database (under the heading 'Data').

In 2019, hepatitis C had the highest death rate among the different main etiologies of liver diseases globally, responsible for approximately 4.8 deaths per 100,000 population. Alcohol followed, with a death rate of 4.5 deaths per 100,000 population. This statistic shows the age-standardized death rates associated with chronic liver disease/cirrhosis in 2019 worldwide, by etiology.

Death rate of a population adjusted to a standard age distribution. As most causes of death vary significantly with people's age and sex, the use of standardised death rates improves comparability over time and between countries, as they aim at measuring death rates independently of different age structures of populations. The standardised death rates used here are calculated on the basis of a standard European population (defined by the World Health Organization). Detailed data for 65 causes of death are available in the database (under the heading 'Data').

According to Cognitive Market Research, the global Liver Cirrhosis Market size will be XX million by 2033, whereas its compound annual growth rate (CAGR) will be XX% from 2025 to 2033. • North America held the largest share of the global Liver Cirrhosis market around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Europe accounted for a share of over XX% of the global market size of USD XX million. • Asia Pacific held a market share of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • The Latin American market is around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033. • Middle East and Africa held the major market of around XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2025 to 2033.

Market Dynamics of the Liver Cirrhosis Market

Key Drivers of the Liver Cirrhosis Market

Increased incidence of liver disease significantly boosts the market

Globally, liver disease is still exceedingly prevalent. A sedentary lifestyle, lack of exercise, and particularly poor food are the main causes of liver disease in many people. As the population ages, autoimmune disorders including hepatitis and non-alcoholic fatty liver are becoming more common. The notable rise in instances can also be attributed to alcohol intake above. The global market for liver disease treatment will be driven by the rising availability of medicines. • For instance, as per the National Center for Biotechnology Information (NCBI), liver disease claims about 2 million deaths globally, every year. Currently, Cirrhosis is the 11th most common cause of death. (Source:https://pubmed.ncbi.nlm.nih.gov/36990226/)

The increasing geriatric population will expand the liver cirrhosis drugs market.

Globally, the aging population is a challenge, and countries are dealing with several issues, such as providing long-term care for those who have a high prevalence of chronic illnesses, such as liver disorders. Maintaining hepatic function, daily living activities, and the quality of life for individuals with liver disease all depend on the management of cirrhosis and hepatitis. The aging-related characteristics must be taken into account while choosing treatment methods and the appropriate dose of currently available medications, even though a wide range of therapeutic choices, including freshly created drugs and procedures, are accessible. • For instance, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. (Source:https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)

Targeted therapies and personalized medicine drive the growth of liver cirrhosis market

Targeted therapies and personalized medicine offer a more precise approach to treating liver cirrhosis, moving beyond one-size-fits-all treatments to consider individual patient profiles and disease characteristics. This approach involves identifying specific molecular pathways, genetic variations, and biomarkers that contribute to cirrhosis and its complications, allowing for the development of drugs and therapies that target these specific mechanisms. Sequencing technologies have made it possible to identify genetic and epigenetic changes in patients with cirrhosis that can be used to inform treatment. Existing standard of care is based on general mechanisms to decrease inflammation in the liver and scarring, but future therapies may be aimed at specific molecular pathways responsible for individual cases. This provides the potential for creating customized treatment plans on the basis of individual patient and disease factors like genotype, disease stage, co-morbidities etc. A number of targeted therapies targeting important mechanisms like TGF-beta inhibition are in pipeline. Future disciplines like RNA therapeutics, gene therapy and regenerative medicine have the potential to provide ...

ABSTRACT BACKGROUND: Sarcopenia is a common complication in patients with cirrhosis and may lead to increased morbidity and mortality. OBJECTIVE: To investigate the prevalence of sarcopenia and its association with disease severity scores, among patients with cirrhosis. DESIGN AND SETTING: Observational and retrospective cohort study carried out in a tertiary-care hospital in southern Brazil. METHODS: This study was conducted among patients with chronic liver disease who were followed up at the gastroenterology and hepatology outpatient clinic of a tertiary-care hospital in southern Brazil and who underwent computed tomography scans of the abdomen through any indication. RESULTS: We included 83 patients in the study. In the population evaluated, there was a predominance of males (57.80%) and the mean age was 56 years. Hepatitis B or C virus was present in the genesis of the disease in 34.9% of the cases, followed by an etiology of alcohol abuse (30.1%). Sarcopenia was diagnosed in 41 (49.4%) of the patients when the cutoff point for cirrhotic patients was used. There was no significant correlation between the Child-Pugh and MELD severity scores and the occurrence of sarcopenia. CONCLUSION: Sarcopenia presents high prevalence among patients with chronic liver disease, without any association with predictors of severity.

In 2019, the global death rate of alcohol-associated liver cirrhosis among the elderly was highest in Africa and the Americas, with around 43 and 26 deaths per 100,000 people, respectively. This statistic shows the age-standardized death rate (ASDR) of alcohol-related liver cirrhosis among the elderly worldwide in 2019, by region.

Directly age and sex standardised mortality rate from liver disease for people aged under 75 in the respective calendar year per 100,000 registered patients.

Current version updated: Sep-16

Next version due: Dec-17

Introduction: The etiology of liver diseases has changed significantly, but its impact on the comparative burden of cirrhosis between males and females is unclear. We estimated sex differences in the burden of cirrhosis across 204 countries and territories from 2010–2019.

Methods: We analyzed temporal trends in the burden of cirrhosis using the methodology framework of the 2019 Global Burden of Disease study. We estimated annual frequencies and age-standardized rates (ASRs) of cirrhosis incidence, death, and disability-adjusted life-years (DALYs) by sex, region, country, and etiology.

Results: In 2019, the frequency of incident cases, deaths and DALYs due to cirrhosis were 1,206,125, 969,068, and 31,781,079 in males, versus 845,429, 502,944, and 14,408,336 in females, respectively. From 2010–2019, the frequency of cirrhosis deaths increased by 9% in males and 12% in females. Incidence ASRs remained stable in males but increased in females, while death ASRs declined in both. Death ASRs for both sexes declined in all regions, except in the Americas where they remained stable. In 2019, alcohol was the leading cause of cirrhosis deaths in males, and hepatitis C in females. Death ASRs declined for all etiologies in both sexes, except in NASH. The ratio of female-to-male incidence ASRs in 2019 was lowest in alcohol(0.5), and highest in NASH(1.3), while the ratio of female-to-male death ASRs was lowest in alcohol(0.3) and highest in NASH(0.8).

Conclusion: The global burden of cirrhosis is higher in males. However, incidence and death ASRs from NASH cirrhosis in females are comparable to that of males.